NO993943L - Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer - Google Patents

Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer

Info

Publication number
NO993943L
NO993943L NO993943A NO993943A NO993943L NO 993943 L NO993943 L NO 993943L NO 993943 A NO993943 A NO 993943A NO 993943 A NO993943 A NO 993943A NO 993943 L NO993943 L NO 993943L
Authority
NO
Norway
Prior art keywords
tumor suppressor
treatment
neoplasms
chemotherapy
combined tumor
Prior art date
Application number
NO993943A
Other languages
English (en)
Norwegian (no)
Other versions
NO993943D0 (no
Inventor
Loretta Nielsen
Jo Ann Horowitz
Daniel C Maneval
William G Demers
Mary Ellen Rybak
Gene Resnick
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of NO993943D0 publication Critical patent/NO993943D0/no
Publication of NO993943L publication Critical patent/NO993943L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
NO993943A 1997-02-18 1999-08-17 Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer NO993943L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US80168197A 1997-02-18 1997-02-18
US80128597A 1997-02-18 1997-02-18
US3806597P 1997-02-18 1997-02-18
US80176597A 1997-02-18 1997-02-18
US80175597A 1997-02-18 1997-02-18
US4783497P 1997-05-28 1997-05-28
PCT/US1998/003514 WO1998035554A2 (fr) 1997-02-18 1998-02-17 Combinaison therapie genique suppressive de tumeurs - chimiotherapie utilisee dans le traitement de neoplasmes

Publications (2)

Publication Number Publication Date
NO993943D0 NO993943D0 (no) 1999-08-17
NO993943L true NO993943L (no) 1999-10-15

Family

ID=27556335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993943A NO993943L (no) 1997-02-18 1999-08-17 Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer

Country Status (19)

Country Link
EP (1) EP0969720B1 (fr)
JP (1) JP2001511815A (fr)
KR (2) KR100620939B1 (fr)
CN (1) CN1248731C (fr)
AT (1) ATE361668T1 (fr)
AU (1) AU737621B2 (fr)
BR (1) BR9807418A (fr)
CA (1) CA2282683A1 (fr)
CZ (1) CZ298488B6 (fr)
DE (1) DE69837754T2 (fr)
ES (1) ES2287974T3 (fr)
HK (1) HK1026579A1 (fr)
HU (1) HUP0004326A3 (fr)
IL (2) IL131447A0 (fr)
NO (1) NO993943L (fr)
NZ (1) NZ337283A (fr)
PL (1) PL193767B1 (fr)
SK (1) SK285969B6 (fr)
WO (1) WO1998035554A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
NZ313828A (en) 1995-07-17 1999-02-25 Univ Texas Expression constructs containing the encoding region of p16 and its regulatory elements and their application in cancer therapy e.g. a replication deficient adenviral vector containing p16
EP1760151B1 (fr) 1996-11-20 2012-03-21 Crucell Holland B.V. Compositions d'adenovirus pouvant être obtenues au moyen d'un procédé de production et purification amélioré
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
PE20000042A1 (es) * 1997-12-22 2000-02-17 Schering Corp Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas
AU762986B2 (en) * 1998-04-22 2003-07-10 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and conventional drugs
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AU3735100A (en) * 1999-03-19 2000-10-09 Schering Corporation Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
EP1354196B1 (fr) * 2000-11-27 2010-09-15 Minerva Biotechnologies Corporation Marqueurs tumoraux de diagnostic, analyse de medicaments pour l'inhibition de la tumorigenese, et compositions et procedes pour le traitement du cancer
EP1340498A1 (fr) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Utilisation d'épothilones dans le traitement de maladies du cerveau associées aux processus de prolifération
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
WO2005082396A2 (fr) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Utilisation de mda-7 pour inhiber des organismes infectieux pathogenes
AU2004305386A1 (en) * 2003-12-24 2005-07-07 Locomogene, Inc. Method of suppressing cancer
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
JP2008518632A (ja) 2004-11-03 2008-06-05 イントロゲン セラピューティックス， インコーポレイテッド アデノウイルスベクターの製造および精製のための新規方法
EP3256494A4 (fr) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Anticorps anti-muc1* humanisés
CN106692989A (zh) * 2017-03-07 2017-05-24 大连民族大学 一种药物脂质体/p53基因复合物及其制备方法和应用
CN109200295A (zh) * 2018-10-08 2019-01-15 蚌埠医学院 一种用于治疗卵巢癌的药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
ZA947969B (en) * 1993-10-15 1996-07-12 Schering Corp Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
JP3193725B2 (ja) * 1995-12-22 2001-07-30 シェーリング コーポレイション Ｇ―タンパク質機能の阻害および増殖性疾患の処置に有用な三環式アミド

Also Published As

Publication number Publication date
CZ298488B6 (cs) 2007-10-17
PL193767B1 (pl) 2007-03-30
NO993943D0 (no) 1999-08-17
HUP0004326A3 (en) 2003-07-28
PL335334A1 (en) 2000-04-25
IL195605A0 (en) 2011-08-01
AU6438098A (en) 1998-09-08
ATE361668T1 (de) 2007-06-15
CZ293399A3 (cs) 2000-03-15
EP0969720A4 (fr) 2004-05-12
IL131447A0 (en) 2001-01-28
KR20050113287A (ko) 2005-12-01
KR100688409B1 (ko) 2007-03-02
HUP0004326A2 (hu) 2001-02-28
CN1252689A (zh) 2000-05-10
BR9807418A (pt) 2002-01-22
EP0969720A2 (fr) 2000-01-12
SK285969B6 (sk) 2007-12-06
JP2001511815A (ja) 2001-08-14
EP0969720B1 (fr) 2007-05-09
DE69837754T2 (de) 2008-02-07
KR100620939B1 (ko) 2006-09-06
WO1998035554A3 (fr) 1998-11-26
HK1026579A1 (en) 2000-12-22
ES2287974T3 (es) 2007-12-16
NZ337283A (en) 2001-02-23
CA2282683A1 (fr) 1998-08-20
CN1248731C (zh) 2006-04-05
WO1998035554A2 (fr) 1998-08-20
KR20000071185A (ko) 2000-11-25
DE69837754D1 (de) 2007-06-21
SK112299A3 (en) 2000-12-11
AU737621B2 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
IL195605A0 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
EP1004022A4 (fr) Methodes et compositions pour surmonter la resistance a une therapie biologique et a une chimiotherapie
HK1030624A1 (en) Enzyme catalyzed therapeutic agents
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
WO2001072962A3 (fr) Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
DE60041592D1 (de) Testverfahren für verbindungen die frühzeitige tra
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
EP1011685A4 (fr) Methode de traitement du cancer par utilisation d'alkylglycerols en association avec la chimiotherapie
ATE285247T1 (de) Krebstherapie mit lymphotoxin
PT1100528E (pt) Utilizacao de novos agentes indutores de morte celular em sinergia com os interferoes
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
DE69735676D1 (de) Proteinmarker für ösophaguskrebs
BR0012301A (pt) Inibidores de crescimento de células epiteliais
WO2000056351A3 (fr) Association therapeutique de gemcitabine et d'un gene suppresseur de tumeur aux fins du traitement de neoplasmes
CO5080825A1 (es) Sistema de terapia con genes suicidas para el tratamiento de tumores cerebrales
DE60023695D1 (de) Tumorsuppressormoleküle und nutzungsverfahren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application